Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AVE 0010

Known as: AVE-0010, AVE0010 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist… Expand
  • table 2
Is this relevant?
2016
2016
Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 5
  • table 1
Is this relevant?
2015
2015
AIMS/INTRODUCTION This was a subanalysis of Japanese patients included in the glucagon-like peptide-1 receptor agonist AVE0010 in… Expand
  • table 1
  • figure 2
  • figure 1
  • table 2
Is this relevant?
2014
2014
AbstractLixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
AIMS To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in… Expand
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2008
2008
We recently showed that insulin analogues exhibit a beta-cell protective function. The aim of this study was to test if the anti… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that is secreted by cells of the lower gastro-intestinal tract following… Expand
Is this relevant?